Abstract:Background: All patients with EGFR mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI). In up to 30% of patients, the mechanism of acquired resistance remains unknown. MicroRNAs (miRNAs) represent a category of small non-coding RNAs commonly dysregulated in human malignancies and have been implicated in therapy resistance. The aim of this study was to understand the role of novel miRNAs in acquired EGFR TKI resistance in EGFR-mutant NSCLC. Method: The miR-483-3p expression in in vitro and in vivo models of acquired gefitinib resistance was examined by miRNA microarray and real-time RT-PCR. Transient or stable gain- and loss-of-function experiments were conducted in cell lines and nude mice, to evaluate the effects of miR-483-3p on sensitivity to gefitinib, proliferation, apoptosis, EMT and migration/invasion in vitro and in vivo. The molecular pathways affected by miR-483-3p were characterized using in silico target prediction, dual luciferase reporter assays and overexpression rescue experiments. The role of promoter methylation in miR-483-3p silencing was examined by real-time RT-PCR after demethylating agents treatment. Result: In this study, we reported the silencing of miR-483-3p and evidence for epithelial-to-mesenchymal transition (EMT) in both in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to gefitinib. In those tumor models, forced expression of miR-483-3p effectively increased sensitivity of gefitinib-resistant lung cancer cells to gefitinib by inhibiting proliferation, promoting apoptosis and reversing EMT phenotype. Mechanistically, miR-483-3p directly targeted integrin beta3, and thus repressed downstream FAK/Erk signaling pathway. In addition, miR-483-3p silencing in gefitinib-resistant NSCLC was due to hypermethylation of its own promoter. Conclusion: Our study provides a novel mechanism that epigenetic silencing of miR-483-3p promotes acquired EGFR TKI resistance in EGFR-mutant NSCLC by targeting integrin beta3. miR-483-3p may present a promising therapeutic target to overcome acquired resistance.The work was supported by National Natural Science Foundation of China (81372522 and 81773747), Science and Technology Commission of Shanghai Municipality (12ZR1416000 and 12140901400).

IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer

Integrin Β1-Mediated Acquired Gefitinib Resistance in Non-Small Cell Lung Cancer Cells Occurs Via the Phosphoinositide 3-Kinase-dependent Pathway.

Role of Insulin-Like Growth Factor 1 in Drug Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer

Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.

The Role of Up-Regulation of Integrin Β1 in Resistance to Gefitinib in Non-Small Cell Lung Cancer

Beta 1 Integrin Mediated Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Lung Cancer Cells

Integrin Β1 Participates in Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer

Gefitinib-Resistance is Related to Bim Expression in Non-Small Cell Lung Cancer Cell Lines

Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer

Β-Catenin Overexpression is Associated with Gefitinib Resistance in Non-Small Cell Lung Cancer Cells.

FGFR Leads to Sustained Activation of STAT3 to Mediate Resistance to EGFR-TKIs Treatment

Induced IGF-1R Activation Contributes to Gefitinib Resistance Following Combined Treatment with Paclitaxel, Cisplatin and Gefitinib in A549 Lung Cancer Cells.

Integrative Analysis of Proteome and Ubiquitylome Reveals Unique Features of Lysosomal and Endocytic Pathways in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells.

ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells.

Metabolic reprogramming driven by IGF2BP3 promotes acquired resistance to EGFR inhibitors in non-small cell lung cancer

Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance in EGFR-mutant NSCLC by targeting integrin beta3

Phosphorylated Insulin-Like Growth Factor 1 Receptor is Implicated in Resistance to the Cytostatic Effect of Gefitinib in Colorectal Cancer Cells

Identification of Hub Genes and Small Molecule Drugs Associated with Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer

An Autocrine IL-6/IGF-1R Loop Mediates EMT and Promotes Tumor Growth in Non-small Cell Lung Cancer

An Integrative Analysis of the Putative Gefitinib-resistance Related Genes in a Lung Cancer Cell Line Model System

Foxm1 Mediated Resistance to Gefitinib in Non-Small-Cell Lung Cancer Cells